Starpharma to recoup $6 million cash for overseas R&D
Starpharma today announced that following a submission to AusIndustry, it is eligible to receive approximately $6 million cash in R&D tax incentive for overseas R&D activities.
Herald Sun: In The Black
The Herald Sun’s Chief Business Writer John Beveridge reported on Starpharma’s announcement that a breast cancer study in mice which showed that adding dendrimers to the chemotherapy drug docetaxel led to drug concentrations within tumours of more than 40 times compared to using the drug alone.
John also profiles the technology platform – “Starpharma has built three exceptional opportunities, all of which promise significant revenue…” The sleeper in the Starpharma portfolio is using dendrimers to improve a range of agricultural chemicals, starting with the herbicide glyphosate.
Starpharma presenting at Bell Potter LifeScience Conference
Starpharma will today present at the Bell Potter LifeScience Conference for professional and sophisticated investors.
The conference is expected to be attended by more than 150 people including the leading institutional investors, high net-worth investors, and other influential industry players.
Starpharma recognised for outstanding year with Janssen 2012 Company of the Year Award
Starpharma was last night named the industry’s 2012 Australian Company of the Year.
The Janssen 2012 Industry Excellence Awards were announced in Melbourne at Australia’s largest industry conference AusBiotech 2012, where Starpharma was awarded the top honour.
Appendix 4C - Quarterly Cashflow report
Starpharma today released its Appendix 4C - Quarterly Cashflow report for the period ended 30 September 2012
Starpharma's new formulations demonstrate further improvement in crop protection
Starpharma today announced that its new agrochemical dendrimer formulations have shown further improved features compared to commercially available products.
The Australian: Criterion - Curing Cancer
Respected Criterion columnist for The Australian Tim Boreham reported on promising results from Starpharma’s latest studies to improve leading cancer drug docetaxel, with its proprietary dendrimer technology. He also commented on Starpharma’s very promising VivaGel portfolio.
Starpharma's docetaxel demonstrates targeted tumour delivery
Starpharma today reported significant tumour-targeting results with its proprietary dendrimer-docetaxel formulation.
VivaGel BV Phase 3 trials - recruitment complete
Starpharma today announced completion of recruitment in its two Phase 3 trials investigating VivaGel® as a treatment for bacterial vaginosis (BV).
Starpharma Signs Cancer Drug Agreement with AstraZeneca
Starpharma today announced the signing of an agreement with global pharmaceutical company AstraZeneca giving AstraZeneca the right to test certain proprietary Starpharma oncology molecules based on Starpharma’s dendrimer technology.